NovellusDx
Jerusalem Bio-Park 5th floor
Hadassah Medical Center Campus, POB 12057
Jerusalem
91120
Website: http://www.novellusdx.com
Email: info@novellusdx.com
About NovellusDx
Founded in 2011, NovellusDX has brought together a team of skilled individuals from several fields, including synthetic biology, functional genomics, bioinformatics, engineering, algorithm development, clinical laboratory and healthcare commercialization.YEAR FOUNDED:
2011
LEADERSHIP:
CEO: Haim Gil-Ad
CCO: Michael Vidne
JOBS:
Please click here for NovellusDx job opportunities.
10 articles about NovellusDx
-
The launch of Fore Biotherapeutics in the U.S. reflects an evolved biotech business model focused on matching patients with unaddressed tumor mutations with the right oncology medicines in the clinic, the company said.
-
Novellus Closes $57M Series C Financing
9/21/2020
Investors include: Pontifax, OrbiMed Advisors, HBM Healthcare Investments, Wellington Management, Cormorant Asset Management, Novartis Venture Fund (NVF), SR One, and existing investors. Proceeds will fund the clinical development of PLX-8394 for patients with BRAF fusions and glioma patients with BRAF mutations. JERUSALEM--( BUSINESS WIRE )-- Novellus, Ltd., a clinical-stage biotechnology company focused on precision oncology announced today
-
Novellus Executes Exclusive Worldwide License Agreement with Plexxikon for PLX8394, Plexxikon’s Next-Generation, Clinical Stage BRAF Inhibitor
6/3/2020
Novellus, a precision-oncology drug development company, announced today that it has entered into an exclusive worldwide license agreement with Plexxikon, a member of the Daiichi Sankyo Group, for PLX8394, its clinical-stage oncology drug candidate which targets the BRAF protein. PLX8394 is currently completing a Ph
-
Chardan Advises NovellusDX in Cross-Border Biotech Merger
9/18/2018
Chardan, a global investment bank, announced today that the firm acted as exclusive financial advisor to NovellusDx., a leader in functional genomics, for the firm's agreement to merge with a newly formed Israeli subsidiary of Cancer Genetics, Inc.. (NASDAQ: CGIX).
-
NovellusDx and Primetech Sign an Exclusive Dealer Agreement in Japan
9/3/2018
NovellusDx, Ltd. and Primetech Co., Ltd. announce that Primetech will provide NovellusDx' functional genomics assay "FACT – Functional Annotation for Cancer Treatment" as an exclusive dealer in Japan for the pre-clinical market with sales, marketing and research support / technical support in Japan.
-
Helsinn Investment Fund, Bio Capital Impact Fund and Windham Venture Partners Join a Leading Investor Syndicate to Support the Commercialization Efforts Of NovellusDx
4/30/2018
NovellusDx announced it has completed an equity financing of $6 million.
-
NovellusDx to perform retrospective analysis of the MOST clinical trial to test the predictive ability of its functional assay in cancer patients.
2/26/2018
Centre Léon-Bérard and the biotechnology company NovellusDx are collaborating on a retrospective analysis of two study arms of the MOST trial.
-
New Partnership Between Christiana Care’s Gene Editing Institute And NovellusDx Speeds Progress Toward Personalized Cancer Medicine
7/20/2017
-
NovellusDx Announced Today The Completion Of The First Phase Of An In-Vitro Study Of BioMed Valley Discoveries' BVD523
6/21/2017
-
NovellusDx Registers Another Patent On Their FACT System, Publishes A New Study With Guardant Health And MD Anderson Cancer Center In Cancer Discovery; Was Selected To Present At Biomed, BIO 2017 And ASCO
5/23/2017